What Pharma Leaders Discuss at AUTOMA+ 2026
The Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) 2026 takes place in Zurich on 16-17 November and reflects companies' approach to digital transformation as a business and operational priority. The Congress addresses major industry developments, including automation, AI adoption, integrated digital ecosystems and patient-focused innovation, through real implementation experience and cross-industry collaboration.
AUTOMA+ has a closed-door format designed to support business decision-making by connecting pharmaceutical companies with technology partners, implementation and operational expertise across automation and digitalisation projects.
“Open discussion of customer challenges creates space for honest dialogue” - Securikett.
This environment encourages transparent exchange around operational barriers, solution strategies and long-term cooperation opportunities.
“AUTOMA+ provides confidence in identifying relevant service providers and highlights the importance of direct interaction with software developers working across multiple technology domains” - RidNova Pharmaceuticals.
Bridging gaps between IT, quality, manufacturing and business teams remains a central objective of the Congress. Participation from pharmaceutical manufacturers, engineering companies, startups and international health organisations reflects the multidisciplinary nature of pharmaceutical digitalisation.
“AUTOMA+ is a strategic reference point for understanding automation trends and evaluating organisational digital maturity” - Jacobs Engineering.
In 2026, AUTOMA+ provides a comprehensive view of digital transformation across R&D, manufacturing, packaging and supply chain operations. The agenda highlights how integrated digital ecosystems support faster drug development, more resilient manufacturing and greater supply chain transparency.
A strong emphasis is placed on AI and data-driven innovation, covering:
- laboratory automation;
- digital factory models;
- advanced analytics;
- real-world evidence in drug development and lifecycle management;
- cross-functional collaboration and aligning digital initiatives.
AUTOMA+ 2026 further explores the expanding role of digital health and patient-centric engagement strategies, such as personalised patient interaction, connected health solutions and data-driven commercial models, treatment outcomes and healthcare collaboration.
With its focus on applied use cases, regulatory realities and cross-functional alignment, AUTOMA+ 2026 positions digitalisation as a business and quality-driven transformation rather than a purely technical exercise.
See why industry leaders return - explore real feedback and insights at AUTOMA+ 2026: https://sh.bgs.group/3vd
Source & image Credit: Automa+
